Can a new daily pill slow advanced prostate cancer?
NCT ID NCT07719361
First seen Jul 22, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This early-stage trial tests whether an experimental drug called FX-111 is safe enough to study further in men with metastatic castration-resistant prostate cancer (mCRPC), a form of advanced prostate cancer that no longer responds to standard hormone therapy. Participants take FX-111 by mouth once daily and are monitored for side effects, how the drug moves through the body, and whether it can slow tumor growth. The study aims to find the right dose and gather initial signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called FX-111
- What this could lead to
- If safe and effective, FX-111 could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety and dosing, not on proving the drug works. Side effects are unknown, and many early-stage drugs never advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
NEXT Houston
NOT_YET_RECRUITINGHouston, Texas, 77054, United States
Contact
-
NEXT Oncology
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
NEXT Virginia
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
START Carolinas
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Dallas-Fort Worth
RECRUITINGFort Worth, Texas, 76104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Los Angeles
RECRUITINGLos Angeles, California, 90025, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START New Jersey
RECRUITINGEast Brunswick, New Jersey, 08816, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Oncology
NOT_YET_RECRUITINGNashville, Tennessee, 37203, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- Can a Two-Drug attack stall resistant prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- Radiation plus hormone therapy may slow resistant prostate cancer
- Targeted radiation zaps prostate cancer cells in new trial
- Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival